Patient, donor, and transplant characteristics
| Characteristics . | Values . |
|---|---|
| Follow-up for survivors, median (range), d | 225 (56-841) |
| Patient age, median (range), y | 46.5 (25-77) |
| Patient sex, male (%) | 16 (57) |
| Type of diagnosis, n (%) | |
| Myeloid lineage | |
| AML | 11 (39) |
| MDS | 3 (11) |
| MF | 3 (11) |
| Other | 1 (3) |
| Lymphoid lineage | |
| NHL | 6 (22) |
| ALL | 2 (7) |
| MM | 2 (7) |
| Disease status at HSCT, n (%) | |
| CR | 17 (61) |
| Active disease | 11 (39) |
| DRI at HSCT, n (%) | |
| Intermediate | 13 (47) |
| High | 14 (50) |
| Very high | 1 (3) |
| Median HCT.CI score (range) | 2 (0-6) |
| Type of donor, n (%) | |
| Sibling | 15 (54) |
| UD 10/10 | 11 (39) |
| UD 9/10 | 2 (7) |
| Female donor/male recipient, n (%) | 4 (14) |
| Host/donor CMV serostatus, n (%) | |
| +/+ | 19 (68) |
| +/− | 2 (7) |
| −/+ | 3 (11) |
| −/− | 4 (14) |
| Stem cell source, n (%) | |
| PB | 28 (100) |
| Infused CD34+, median (range) | 5 × 106/kg (4-7) |
| Infused CD3+, median (range) | 189 × 106/kg (53-456) |
| Conditioning regimen details, n (%) | |
| Treo-Flu-Mel | 27 (97) |
| Treo-Thio-Flu | 1 (3) |
| GVHD prophylaxis details, n (%) | |
| PTCy − sirolimus + MMF | 13 (46) |
| PTCy − sirolimus | 15 (54) |
| Characteristics . | Values . |
|---|---|
| Follow-up for survivors, median (range), d | 225 (56-841) |
| Patient age, median (range), y | 46.5 (25-77) |
| Patient sex, male (%) | 16 (57) |
| Type of diagnosis, n (%) | |
| Myeloid lineage | |
| AML | 11 (39) |
| MDS | 3 (11) |
| MF | 3 (11) |
| Other | 1 (3) |
| Lymphoid lineage | |
| NHL | 6 (22) |
| ALL | 2 (7) |
| MM | 2 (7) |
| Disease status at HSCT, n (%) | |
| CR | 17 (61) |
| Active disease | 11 (39) |
| DRI at HSCT, n (%) | |
| Intermediate | 13 (47) |
| High | 14 (50) |
| Very high | 1 (3) |
| Median HCT.CI score (range) | 2 (0-6) |
| Type of donor, n (%) | |
| Sibling | 15 (54) |
| UD 10/10 | 11 (39) |
| UD 9/10 | 2 (7) |
| Female donor/male recipient, n (%) | 4 (14) |
| Host/donor CMV serostatus, n (%) | |
| +/+ | 19 (68) |
| +/− | 2 (7) |
| −/+ | 3 (11) |
| −/− | 4 (14) |
| Stem cell source, n (%) | |
| PB | 28 (100) |
| Infused CD34+, median (range) | 5 × 106/kg (4-7) |
| Infused CD3+, median (range) | 189 × 106/kg (53-456) |
| Conditioning regimen details, n (%) | |
| Treo-Flu-Mel | 27 (97) |
| Treo-Thio-Flu | 1 (3) |
| GVHD prophylaxis details, n (%) | |
| PTCy − sirolimus + MMF | 13 (46) |
| PTCy − sirolimus | 15 (54) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CR, complete remission; DRI, disease-risk index17 ; Flu, fludarabine; HCT.CI, hematopoietic cell transplantation comorbidity index12 ; MDS, myelodysplastic syndrome; Mel, melphalan; MF, myelofibrosis; MM, multiple myeloma; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma; PB, peripheral blood; Thio, thiotepa; Treo, treosulfan; UD, unrelated donor.